Epilepsy treatment: precision medicine at a crossroads.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Prediction of personalized antiseizure medications response based on clinical signatures in epilepsy.Scientific reports · 2025
   Article
2. Reversing Accumulation of Polyglucosan Bodies by Virally Delivered CRISPR/Cas9 Genome Editing.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
   Article
3. Next-generation sequencing improves treatment efficacy and reduces hospitalization in children with drug-resistant epilepsy.CNS neuroscience & therapeutics · 2019
   Article
4. A retrospective study of transcutaneous vagus nerve stimulation for poststroke epilepsy.Medicine · 2018
   Article

Corrections and comments

• Comment on
  A roadmap for precision medicine in the epilepsies.2015

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as